Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 29, 2013

View Archived Issues

A prognostic peptide-based signature for end-stage renal disease in fetal urinary output

Medimmune to acquire Amplimmune

AiCuris presents a novel class of antibacterial compound with potent activity

An oral multikinase inhibitor shows potent antiangiogenic activity in vivo

Carolus and TAP seek to validate RANTES:Pf-4 as CT-2009 target

Acucela's SEATTLE study reaches half way enrollment

TRPM8 blockade as a potential new treatment strategy for urinary bladder disorders

Licensing and codevelopment agreement for NovaBiotics' first-in-class antifungal peptide

Lee's Pharmaceutical submits CTA to expand the APEX study to China

Orexo updates on OX-51 phase II dose-finding study

Arena Pharmaceuticals completes phase Ib APD-811 trial

FDA accepts for review dabigatran supplemental NDA

U.K.'s NICE does not recommend everolimus use by NHS

Cepheid's Xpert MTB/RIF test categorized by FDA

The University of Virgina presents new sphingosine kinase inhibitors

Novel EGFR inhibitors disclosed by Taiho Pharmaceutical

Scientists at Innate Pharma divulge new MAbs for cancer

Sunovion Pharmaceuticals discloses new antipsychotic agents

FDA extends PDUFA goal date for Xiaflex

Teva decides not to license RX-3117 from Rexahn

Japanese launch for Bonviva injection

Phase II trial planned for CF-102 in hepatocellular carcinoma

Daiichi Sankyo files marketing application for Ranmark in Japan

Grifols and Aradigm close worldwide licensing agreement for inhaled formulations of ciprofloxacin

Europe Commission approves Eylea for visual impairment complications following CRVO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...